Teva Confident On US Adalimumab Filing Amid Alvotech Advantages
‘Out Of Maybe Seven Competitors, Three, Maybe Four, Will Really Get Going’
A delay in FDA approval for partner Alvotech’s proposed high-concentration biosimilar version of Humira has not concerned Teva, especially after the product was approved by the EMA at the end of last year. There “shouldn’t really be any challenges here,” management says.
